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ABSTRACT
Objectives: The study aims to assess how evidence on diagnostic test
accuracy is synthesized and used to inform economic decision modeling
for HTA.
Methods: All reports evaluating diagnostic test via an economic decision
model published by the NHS Research and Development Health Technol-
ogy Assessment (HTA) program since 1997 were identiﬁed. The methods
for evidence synthesis of diagnostic test accuracy data and its use in
economic decision modeling in this sample were reviewed.
Results: Forty-four HTA reports out of 474 concerned diagnostic accu-
racy, of which 11 did not do any economic evaluation. Of the remaining
33 HTAs, 14 conducted meta-analyses of diagnostic accuracy in the clini-
cal review but only 8 used such pooled estimates to inform the decision
model. A number of meta-analysis methods ranging in complexity were
applied to estimate diagnostic accuracy. Nevertheless, when it came to
informing the economic decision model, the majority of reviews used
independent meta-analytic estimates of sensitivity and speciﬁcity.
Conclusions: Often, very simplistic methods to estimate diagnostic test
accuracy were used for purposes of informing an economic decision
model. The assumptions made by the simplistic methods are usually
invalid which may lead to suboptimal decisions being made. It is desirable
that decision modelers become aware of the rapid evolution of meta-
analysis methods in this area; however, further research is still required to
identify how the pooled results obtained from the different meta-analysis
models should best be used to inform economic decision models.
Keywords: decision models, diagnostic test accuracy, economic evalua-
tion, health technology assessment.
Introduction
The creation of structures in the UK (i.e., National Institute for
Health and Clinical Excellence) and elsewhere to facilitate
evidence-based health policy decision-making has highlighted the
role that systematic reviews including, where appropriate, meta-
analysis, and economic evaluations have to play in the decision-
making process. These methodologies provide answers to
fundamental questions such as: Does the technology work, for
whom, at what cost, and how does it compare with alternatives
[1]? In the area of diagnostic test performance, such evidence-
based evaluations are crucial to the decision-making process as
early diagnosis can lead to diseases being treated more success-
fully than if treatment were delayed.
Diagnostic test accuracy is deﬁned as the ability of a test to
distinguish between patients with a speciﬁed target condition and
those without [2]. The results of a diagnostic test accuracy study
are usually expressed in terms of sensitivity (i.e., the proportion
of people with the condition correctly detected by the test) and
speciﬁcity (i.e., the proportion of people without the condition
correctly detected by the test), the positive predictive value (i.e.,
the proportion of people with positive test results who have the
disease) and negative predictive value (i.e., the proportion of
people with negative test results who do not have the disease), the
likelihood ratios for the respective test results or the receiver-
operating characteristic (ROC) curve [3]. The ROC curve
(Fig. 1b) provides a plot of sensitivity versus (1-speciﬁcity) to
highlight the covariation between the two outcomes. The best
diagnostic tests will be those that maximize both sensitivity and
speciﬁcity (i.e., positioned in the upper-left corner of the ROC
space where both sensitivity and speciﬁcity are close to one) [2].
Evidence synthesis of diagnostic test accuracy data are more
complicated than for intervention studies because of additional
issues relating to variable test threshold levels, dependence
between outcomes (i.e., sensitivity and speciﬁcity), and use of
multiple tests in combination. To date, at least six different
approaches to the meta-analysis of studies reporting pairs of
sensitivity and speciﬁcity estimates have been developed, each
producing results in different formats (Fig. 1). The approaches
are next described brieﬂy in order of sophistication. For a more
technical description, see Deeks [3] (methods 1, 2, and 3),
Harbord et al. [4] (methods 4 and 5), Dukic and Gatsonis [5],
and references therein:
1. Independent meta-analyses of sensitivity and speciﬁcity
assuming independence of the two [6]. Because there is
usually a trade-off to be made between sensitivity and speci-
ﬁcity which is done by varying the threshold value used to
categorize diseased and nondiseased (i.e., when high test
results are positive, decreasing the threshold value will
increase sensitivity and lower speciﬁcity, and vice versa),
this method is only valid if all primary studies report test
performance using the same threshold. This method pro-
duces a summary point on the ROC plane for the pooled
sensitivity and speciﬁcity (Fig. 1a).
2. Meta-analysis of diagnostic odds ratios [6]. This method
relaxes the assumption that all studies use the same test
threshold. In doing so, this method produces a symmetric
summary receiver operating curve (sROC) (Fig. 1b). This
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assumes that the variances of the distributions of test values
are the same in both the diseased and nondiseased popula-
tions.
3. sROC regression modeling approach of Littenberg and
Moses [7]. This approach extends the previous one-
parameter model to a two-parameter model; that is, a
further parameter is included to allow the sROC to be
asymmetric (Fig. 1c). The limitations of this approach
include: 1) its failure to fully account for the uncertainty in
the data; and 2) it is a ﬁxed effect method and hence any
between-study heterogeneity is ignored [2].
4. Hierarchical sROC model. This model essentially extends
regression method 3 to allow for heterogeneity (beyond that
accounted for by differences in thresholds between studies)
in performance between studies, allowing each study to be
assumed to be sampled from a distribution of sROC curves
[8] (Fig. 1d, sROC curve).
5. Bivariate meta-analysis models. This random effects model
models sensitivity and speciﬁcity and their correlation
within a single model [8,9]. This produces a joint conﬁdence
region around the pooled sensitivity and speciﬁcity [4]
(Fig. 1d, dotted conﬁdence region). It has been shown
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Figure 1 Illustration of the different formats of the analysis output obtained when the ﬁve alternative approaches to meta-analysis of diagnostic test data are applied.
(a) Independent meta-analyses of sensitivity and speciﬁcity. (b) Meta-analysis of diagnostic odds ratios. (c) sROC regression modeling approach. (d) Bivariate and
hierarchical sROC models. sROC, summary receiver operating curve.
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recently that the hierarchical sROC model (method 4) and
the bivariate model are mathematically equivalent [4]
(although the two parameterisations lead naturally to the
different parameter summaries presented in Fig. 1d).
6. Synthesis of test performance at multiple thresholds from
the individual studies [5]. Although rarely done in practice,
it is possible to extend the hierarchical sROC model to
include multiple data points from the primary studies relat-
ing to multiple test thresholds to produce an overall sROC
curve (not shown graphically).
Note that study level covariates could be added to any of the said
models in an attempt to explain between-study heterogeneity. As
the format of the results produced by each of the different meta-
analysis models differs considerably (Fig. 1), the challenge when
evaluating the cost-effectiveness of diagnostic tests is how best to
synthesize the available evidence and then appropriately incor-
porate the results of this synthesis in an economic decision
model. Recent guidance from the Cochrane Diagnostic Test
Accuracy Group advises reviewers to use the hierarchical sROC
(method 4) or the bivariate model (method 5) as both of these
methods overcome the limitations of methods 2 and 3 outlined.
The Group discredits method 1 because such an approach may
identify a summary point that is not representative of the paired
sensitivity and speciﬁcity data (that is, a point that does not lie on
the sROC curve). In this article, we investigate how evidence on
test accuracy is used to inform decision models developed to
evaluate the cost-effectiveness of diagnostic tests. In particular,
we focus on diagnostic tests evaluated as part of the NHS
Research and Development Health Technology Assessment
(HTA) program since 1997 and investigate how the evidence on
diagnostic test accuracy identiﬁed as part of the systematic
review is used to inform the diagnostic test accuracy parameter(s)
of the economic decision model. Where evidence synthesis
methods have been applied to combine test accuracy data from a
number of studies, the review focuses on the speciﬁc meta-
analysis models adopted and how these pooled results are used in
the economic evaluation, if at all.
Methods
All NHS Research & Development HTA program reports listed
on their website (http://www.ncchta.org/project/htapubs.asp) as
published between 1997 and May 2009 inclusively were
reviewed by one of the authors (NN) with the aim of identifying
reports that evaluated the performance of diagnostic tests. First,
the HTA reports were categorized, based on their title, as: 1)
Methodology; 2) Treatments alone; or 3) Testing. Where classi-
ﬁcation was unclear from the title, abstracts followed by execu-
tive summary and then introduction were reviewed as necessary.
The second step was to subdivide those HTA reports classiﬁed
as Testing into one of the following subgroups: 1) Diagnosis; 2)
Screening; 3) Prognosis; and 4) Monitoring. Occasionally, a
report could be classiﬁed into more than one subgroup. If a
report contained diagnosis and prognosis, screening or monitor-
ing, then the report was classiﬁed as diagnosis. For all other
combination, the report was classiﬁed according to its main
objective established by reading the main text of the report.
Where the purpose(s) of the testing was unclear, categorization
was established via consensus forming discussions with two
further authors (NJC and AJS).
All reports evaluating diagnostic tests were reviewed to iden-
tify whether an economic decision model had been developed as
part of the HTA. Those reports where economic models had been
developed were examined further to establish whether they con-
tained meta-analyses of diagnostic accuracy data in the clinical
review section of the report. Those that had deﬁned our sample
of interest, and these reports were scrutinized further. Speciﬁcally,
data were extracted on:
1. all meta-analysis methods used in the clinical review;
2. whether any of the meta-analysis methods recorded in point
1 above were used to derive estimates of test performance
for the economic model. If yes, which method used. If no,
the alternative method used to estimate diagnostic test accu-
racy parameters speciﬁcally for the economic model; and
3. whether the economic model had considered pathways
involving multiple test combinations, and if so, how test
performance had been estimated for the combinations of
tests.
Results
Figure 2 shows our classiﬁcations of the 474 HTA reports pub-
lished between 1997 and May 2009 inclusively. A total of 110
out of the 474 reports (23%) were classiﬁed as “Testing,” with
44 (40%) of these focusing on “Diagnosis.” A total of 33 out of
the 44 “Diagnosis” reports (75%) included an economic evalu-
ation. Of these 33, 14 (42%) included meta-analysis of diagnos-
tic test accuracy in the clinical review section of the report and
these 14 reports deﬁne our sample of interest (a numbered ref-
erence list [S1–14] for this sample is provided in the appendix
at: http://www.ispor.org/Publications/value/ViHsupplementary/
ViH13i8_Cooper.asp).
In Table 1, the 14 reports that performed meta-analysis as
part of the clinical review are listed chronologically together with
the meta-analysis method(s) used (denoted by the letter R in the
table). The methods are listed broadly in order of complexity and
it can be observed that most reports used more than one meta-
analysis method. All of the reports, except one (S9), included
independent meta-analyses on speciﬁcity and sensitivity, thus
assuming the two measures to be independent. One of these
reports used individual participant data in its meta-analysis
rather than summary data (S13). Two reviews adopted a strategy
based on heterogeneity; that is, where evidence of heterogeneity
existed, the Littenberg and Moses regression approach was
adopted, otherwise independent pooled estimates of sensitivity
and speciﬁcity were obtained (S1, S6). The most sophisticated
methods of bivariate and hierarchical sROC were only applied
by two of the reviews (S9, S10). Five of the reports considered
study-level covariates in their analyses (S4, S5, S9, S14, S15).
Table 1 also highlights which meta-analysis method (if any) is
used to inform the test accuracy parameters in the economic
decision model (denoted by the letter M in the table). Where the
letters R and M appear in the same cell of the table, this indicates
that one of the meta-analysis approaches used in the clinical
review was also used to inform the economic decision model.
Where the letter M appears in a cell on its own, this indicates that
a different meta-analysis method was used speciﬁcally to inform
the decision model.
A total of 8 out of 14 reports (57%) used independent
pooled estimates of sensitivity and speciﬁcity obtained from
meta-analyses performed in the clinical review as inputs into
the decision model; 5 (36%) used study data identiﬁed by the
clinical review but performed their own meta-analyses (3 out of
5 reports did independent meta-analyses on sensitivity and
speciﬁcity, 1 out of 5 report did a bivariate meta-analysis
model, and 1 out of 5 report obtained negative predictive
values and ratio of test positive to test negative); and 1 report
used sources external to the clinical review plus consensus
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opinion. Overall, the majority of reports (10 out of 14 [71%])
used pooled estimates of sensitivity and speciﬁcity obtained
from the simplest meta-analysis method, that assumes the two
measures are independent of one another, as inputs into the
economic decision model. Only two economic decision models
used estimates of sensitivity and speciﬁcity from meta-analyses
that allowed for the correlation between the two quantities
attributed to test thresholds varying between studies (i.e., a
bivariate model). None of the models used a meta-analysis
method that derives an sROC (i.e., Diagnostic odds ratio, Lit-
tenberg and Moses regression method, hierarchical sROC
curve). A total of 10 out of the 14 models reviewed (77%)
incorporated the uncertainty associated with pooled estimates
to perform a probabilistic cost-effectiveness evaluation.
Figure 2 Flowchart of excluded and included
studies.
Table 1 Meta-analysis methods applied in the systematic review of diagnostic test accuracy (R) and results used as input parameter in the economic
decision model (M)
HTA report
Volume/number
2002 2004 2006 2007 2008 2009
Meta-analytic methods used to evaluate diagnostic accuracy S2 S7 S6 S11 S8 S5 S12 S13 S14 S3* S1 S9 S10 S4†
Independent sensitivity and speciﬁcity M R, M R, M‡ R, M R, M R, M M§ R, M R R M R, M R
Likelihood ratio R R R R R R R
Diagnostic odds ratio R R R R R
Littenberg and Moses regression approach R R R
Littenberg and Moses if heterogeneity, if not independent R R
Bivariate model M¶ R, M**
Hierarchical Summary Receiver Operating Characteristic curve R
*Used data from systematic review to obtain negative predictive values (number of true negatives divided by total number of negatives) and ratio of test positives to test negatives.
†Used data from external sources and consensus opinion.
‡Used median sensitivity and speciﬁcity.
§Expert opinion used where no studies identiﬁed in the systematic review.
¶Performed a series of regression analyses to establish the relationship between sensitivity and speciﬁcity.
**Unclear how the bivariate data are dealt with in the probabilistic decision model.
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Evaluation of a Combination of Diagnostic Tests
A total of 6 out of the 14 (43%) reports listed in Table 1 con-
sidered a combination of diagnostic tests in the economic deci-
sion modeling. Two of these (S8, S13) assumed the tests to
perform independently of one another and thus input the pooled
estimates of sensitivity and speciﬁcity obtained for each test
direct from the meta-analyses. Two reports (S3, S14) assumed the
second test to have 100% sensitivity and 100% speciﬁcity (i.e., a
perfect test). Only one report (S5) clearly stated that the speci-
ﬁcity of a second test (d-dimer) depended on the result obtained
from the ﬁrst test (Wells criteria). This was possible due to the
data available; that is, a number of studies reported the sensitiv-
ity and speciﬁcity of the d-dimer stratiﬁed by the Wells score [10]
(test performance was assumed independent for all other test
combinations evaluated in this report). The remaining report
(S12) provided no details about how the combination of tests
was evaluated.
Discussion
The focus of this review has been to assess how evidence on test
accuracy is synthesized and used to inform economic decision
models evaluating diagnostic pathways. The 14 HTA reports
reviewed here were all published in the last 7 of the 12-year
period considered suggesting that economic evaluation of diag-
nostic tests via decision models is in its infancy. Because of this,
it is perhaps not surprising that little has been written on the
associated methodology [11].
Many of the reports used a range of different meta-analysis
methods to synthesize the test performance data. This in itself
can be problematic because virtually all the methods make dif-
ferent assumptions, and therefore, theoretically cannot simulta-
neously be appropriate for a given dataset. Ideally, authors
should assess how well each of the proposed models ﬁts the data
to identify the “best” ﬁtting model and thus facilitate interpre-
tation regarding the most appropriate summary of test perfor-
mance [N. Novielli et al., unpublished data]. Multiple methods
were used in many of the clinical reviews but, despite this, the
majority of the reports applied the simple meta-analytic
approach of assuming sensitivity and speciﬁcity to be indepen-
dent for informing the decision model. This is concerning
because it has been established that when this model is used
inappropriately (i.e., the primary studies evaluate tests at differ-
ent thresholds), the resulting point estimate underestimates true
test performance [3] (i.e., it lies below the sROC curve that
would be produced by an analysis that takes threshold into
account). Additionally, if a probabilistic modeling approach is
used, this approach will estimate the uncertainty incorrectly.
Although half the reports calculated pooled likelihood ratios
for test performance; none went on to use these estimates to
inform the decision model. This is understandable because it is
not as straightforward to use likelihood ratios compared to
estimates of sensitivity and speciﬁcity to estimate the number of
true positives, true negatives, false positives, and false negatives
required by the typical parameterization of decision models
evaluating diagnostic tests. Similarly, although methods that
estimate an sROC curve (i.e., diagnostic odds ratios and the
regression method of Littenberg and Moses) were conducted
quite frequently, the output from these analyses was never used
to inform the decision model. Again, this may well be because
it is not obvious how to parameterize output in the form of an
sROC curve in the decision model. Indeed, one report (S13)
stated that meta-analyses were performed on sensitivity and
speciﬁcity separately, rather than calculating an sROC curve, to
obtain the parameters needed for the economic decision model.
An sROC curve describes how test performance varies with
changing test threshold, therefore it would be possible to con-
sider the cost-effectiveness of a diagnostic strategy as a function
of test threshold. This could be achieved most simply by
running a series of decision models using estimates of sensitivity
and speciﬁcity for the test(s) at different locations on the sROC
curve. In this way, it is possible to identify the optimum
threshold—in terms of cost-effectiveness—to use a test at
(although it should be acknowledged that, in practice, specify-
ing an exact threshold may or may not be achievable). To our
knowledge, this approach has only been attempted once in the
published literature [11].
A bivariate model, which accounts for the correlation
between sensitivity and speciﬁcity, was used in two of the reports.
There would appear to be growing consensus in the statistical
literature that this is the most appropriate model for meta-
analyzing test performance data [4,12]. Therefore, this ﬁnding
could be interpreted as disappointing. Nevertheless, it is impor-
tant to remember that this approach to meta-analysis of diag-
nostic test data was only described in the literature in 2005 [9],
with custom software appearing even more recently (e.g., a
macro for Stata [13]). It is important to appreciate that it is likely
that the research for the HTA reports reviewed here was under-
taken before the publication of this key article [9] in the majority
of cases.
Even once the parameter estimates for the bivariate model
have been obtained, for a probabilistic decision model, it will be
necessary to specify a multivariate normal distribution or a repa-
rameterization or approximation to it that is nontrivial (i.e., one
of the articles stated using Cholesky Decomposition for this
[S14]). Alternatively, it is possible to use a one-stage comprehen-
sive approach to the decision modeling where the meta-analyses
are carried out simultaneously in the same computer program
that evaluates the decision model. This has been described else-
where [11] using the WinBUGS software [14] which implements
MCMC simulation methods, and perhaps provides the most
elegant approach available to date.
Despite the above, it is the authors’ belief that the bivariate
approach should not be used uncritically for the following
reason. The method estimates a 95% conﬁdence region for the
average sensitivities and speciﬁcities observed in the primary
studies. Therefore, it is implicit that all the studies are represen-
tative of how the test will be used in routine practice. If for
example, particular studies use test thresholds which are not
representative of routine practice/a particular threshold being
considered, then such an analysis would seem inappropriate. In
such cases, exploring cost-effectiveness as a function of an sROC
curve, or at one particular point on the curve, would seem more
appropriate (although, study level data relating to test threshold
is not routinely included in the meta-analysis models and there-
fore it is not obvious which point on an sROC curve relates to a
particular threshold). Given this, further research is required to
establish the optimal approach in different situations and this is
ongoing.
To add further confusion to this already complex area, it was
recently established that the bivariate model and the hierarchical
sROC approach are actually reparameterizations of the same
model [4] although the two parameterizations lead naturally to
different model summaries (i.e., a conﬁdence region in ROC
space and an sROC curve, respectively). Thus, owing to this
reparameterization, it is possible to obtain an sROC curve from
the bivariate analysis and therefore the discussion relating to
sROC curves previously is also pertinent for this model leading
to even more possibilities of how diagnostic test data may be
used to inform decision models.
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How the application of the different synthesis methods would
affect the conclusions in any particular decision problem is dif-
ﬁcult to predict because multiple tests may be compared in an
economic decision model, and the synthesis estimates of test
performance may be deﬁcient in similar ways (i.e., due to the
problems highlighted previously). In a previous article [11], the
application of the different synthesis methods to a particular
decision problem (which incidentally is reference S5 in the
current article and included in the review) is explored. Here, the
initial HTA assumed independent ﬁxed estimates of sensitivity
and speciﬁcity but alternative approaches were compared to this.
In this example, only relatively small changes in the cost-
effectiveness acceptability curves were observed and the decision
would not change for most willingness to pay thresholds, but the
impact may be considerably greater in other contexts; for
example, where the accuracy (and costs) of the competing test
strategies are more similar than d-dimer and ultrasound are in
this example.
Six of the models reviewed considered diagnostic pathways
using multiple tests in combination. The use of combinations of
tests is common in clinical practice, e.g., a cheap or noninvasive
test may initially be used which has poor speciﬁcity and those
diagnosed as diseased may go on to receive a more expensive/
more invasive test with superior test performance. We are con-
cerned that estimation of accuracy of test combinations was dealt
with too simplistically in these reviews (i.e., assuming tests to be
independent or the second test to be perfect). Crucially, this is
perhaps a limitation of the available data as much as the mod-
eling per se as many primary studies estimating test performance
only consider a single test so results of tests conditional on the
results of other tests are rarely available. We are concerned that
if the strong assumption of test independence is violated, this
could lead to misleading conclusions. Further work is needed to
establish ways of estimating such correlations. Even if they are
estimated with considerable uncertainty, including them in the
modeling allows the possibility of using value of information
methods [15,16] to demonstrate the importance of conducting
primary studies to estimate them more accurately.
In conclusion, meta-analytic methods for diagnostic test accu-
racy data have developed rapidly in recent years. Decision mod-
ellers need to be aware of the recent developments in this area
and appreciate the limitations of simplistic approaches used com-
monly in the past. Nevertheless, more research is needed to reﬁne
and develop synthesis methods in this context for the purpose of
decision modelling.
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